Citadel Advisors’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-58,000
| Closed | -$4.18M | – | 14044 |
|
|
2025
Q4 | $4.18M | Sell |
58,000
-38,900
| -40% | -$2.51M | ﹤0.01% | 4565 |
|
|
2025
Q3 | $4.22M | Buy |
96,900
+21,200
| +28% | +$857K | ﹤0.01% | 4671 |
|
|
2025
Q2 | $2.15M | Buy |
75,700
+32,600
| +76% | +$972K | ﹤0.01% | 5571 |
|
|
2025
Q1 | $1.27M | Sell |
43,100
-20,300
| -32% | -$632K | ﹤0.01% | 6417 |
|
|
2024
Q4 | $1.84M | Buy |
63,400
+22,000
| +53% | +$919K | ﹤0.01% | 5801 |
|
|
2024
Q3 | $1.9M | Buy |
41,400
+28,800
| +229% | +$1.25M | ﹤0.01% | 5636 |
|
|
2024
Q2 | $515K | Sell |
12,600
-14,300
| -53% | -$410K | ﹤0.01% | 7980 |
|
|
2024
Q1 | $686K | Buy |
26,900
+18,600
| +224% | +$291K | ﹤0.01% | 7708 |
|
|
2023
Q4 | $75.1K | Sell |
8,300
-10,200
| -55% | -$68.2K | ﹤0.01% | 11299 |
|
|
2023
Q3 | $118K | Buy |
18,500
+12,700
| +219% | +$109K | ﹤0.01% | 10682 |
|
|
2023
Q2 | $64.3K | Sell |
5,800
-5,000
| -46% | -$62.7K | ﹤0.01% | 11506 |
|
|
2023
Q1 | $166K | Sell |
10,800
-8,500
| -44% | -$187K | ﹤0.01% | 10479 |
|
|
2022
Q4 | $428K | Sell |
19,300
-37,200
| -66% | -$555K | ﹤0.01% | 8565 |
|
|
2022
Q3 | $923K | Sell |
56,500
-121,700
| -68% | -$2.33M | ﹤0.01% | 7175 |
|
|
2022
Q2 | $2.59M | Buy |
178,200
+78,100
| +78% | +$1.16M | ﹤0.01% | 5033 |
|
|
2022
Q1 | $1.85M | Buy |
+100,100
| New | +$1.7M | ﹤0.01% | 6258 |
|
|
2021
Q4 | – | Sell |
-8,300
| Closed | -$204K | – | 14604 |
|
|
2021
Q3 | $204K | Buy |
+8,300
| New | +$180K | ﹤0.01% | 11949 |
|
Other funds holding RNAM
Citadel Advisors's RNAM Position: Q1 2026 in Review
Citadel Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,592,429 shares — an estimated $115M sold.
Citadel Advisors first reported a position in RNAM in Q2 2020 and held it in 16 quarters. The position peaked at $115M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Citadel Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 1,592,429 Avidity Biosciences shares in Q1 2026, an estimated $115M.
- Citadel Advisors first reported a position in Avidity Biosciences in Q2 2020 and held it in 16 quarters.
- Citadel Advisors's Avidity Biosciences position peaked at $115M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.